Evidence map›Paper›PMID 40080754›Full record

ArticleJCO precision oncology2025

Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid Tumors.

Martina Eriksen, Anne M Hansen, Annelaura B Nielsen, Filip Mundt, Matthias Mann, Ulrik Lassen, Lise B Ahlborn, Martin Højgaard, Iben Spanggaard, Camilla Qvortrup and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Martina EriksenDepartment of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0002-4700-2615
Anne M HansenDepartment of Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Annelaura B NielsenNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.ORCID 0009-0005-2855-208X
Filip MundtNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-8622-2971
Matthias MannNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-1292-4799
Ulrik LassenDepartment of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0002-3865-4574
Lise B AhlbornDepartment of Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0001-8021-7442
Martin HøjgaardDepartment of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Iben SpanggaardDepartment of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0001-5925-2630
Camilla QvortrupDepartment of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Christina W YdeDepartment of Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Kristoffer S RohrbergDepartment of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0002-5448-9003

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIt is a clinical challenge to select patients for BRAF-targeted therapy because of the lack of predictive biomarkers besides the BRAF V600E mutation. By analyzing the genome, transcriptome, and proteome, this study investigated the association between baseline molecular alterations and outcomes of BRAF-targeted therapy. PATIENTS AND

methodsFresh tumor tissue from patients enrolled in the Copenhagen Prospective Personalized Oncology study was collected and underwent comprehensive molecular profiling.

results

conclusionUsing a multiomic approach, we identified molecular alterations associated with treatment outcomes. The potential of analyzing multiomic data is promising and should be prioritized in translational cancer research to uncover the full potential within precision oncology.

Indexed as

Molecular Targeted TherapyNeoplasmsProto-Oncogene Proteins B-rafAdultAgedFemaleHumansMaleMiddle AgedMultiomicsMutationProspective StudiesTreatment OutcomeTumor Suppressor Protein p53BRAF protein, humanProto-Oncogene Proteins B-rafTumor Suppressor Protein p53

Identifiers

PMID40080754
PMCPMC11922189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.